Wuhan Hiteck Biological Pharma Co (SZSE:300683) FCF Margin % : -5.86% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Wuhan Hiteck Biological Pharma Co's Free Cash Flow for the three months ended in Mar. 2024 was ¥-7.7 Mil. Wuhan Hiteck Biological Pharma Co's Revenue for the three months ended in Mar. 2024 was ¥131.9 Mil. Therefore, Wuhan Hiteck Biological Pharma Co's FCF Margin % for the quarter that ended in Mar. 2024 was -5.86%.

As of today, Wuhan Hiteck Biological Pharma Co's current FCF Yield % is -3.38%.

The historical rank and industry rank for Wuhan Hiteck Biological Pharma Co's FCF Margin % or its related term are showing as below:

SZSE:300683' s FCF Margin % Range Over the Past 10 Years
Min: -38.24 Med: -1.35 Max: 21.82
Current: -16.55

During the past 11 years, the highest FCF Margin % of Wuhan Hiteck Biological Pharma Co was 21.82%. The lowest was -38.24%. And the median was -1.35%.

SZSE:300683's FCF Margin % is ranked worse than
75.66% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 0.25 vs SZSE:300683: -16.55

Wuhan Hiteck Biological Pharma Co FCF Margin % Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co FCF Margin % Chart

Wuhan Hiteck Biological Pharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-8.57

-25.44

-38.24

-17.56

-26.92

Wuhan Hiteck Biological Pharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-51.42	-11.01	-35.45	-12.63	-5.86

Competitive Comparison of Wuhan Hiteck Biological Pharma Co's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Hiteck Biological Pharma Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan Hiteck Biological Pharma Co's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wuhan Hiteck Biological Pharma Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Wuhan Hiteck Biological Pharma Co's FCF Margin % falls into.

Wuhan Hiteck Biological Pharma Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Wuhan Hiteck Biological Pharma Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-162.127	/	602.284
	=	-26.92 %

Wuhan Hiteck Biological Pharma Co's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-7.725	/	131.888
	=	-5.86 %

Wuhan Hiteck Biological Pharma Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » FCF Margin %

Traded in Other Exchanges

N/A

Address

Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056

Website

http://www.hiteck.com.cn

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.

Executives

Yan Jie	Director
Li Sheng Qiang	Executives

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Headlines

No Headlines